Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians
Sophie Outh-Gauer(Délégation Paris 5), Cécile Badoual(Inserm), Éric Tartour(Centre National de la Recherche Scientifique), Thomas Denize(Harvard University), Elizabeth Fabre(Assistance Publique – Hôpitaux de Paris), Jérémy Augustin(Université Paris Cité), H. Mirghani(Assistance Publique – Hôpitaux de Paris), Christophe Le Tourneau(Institut Curie), Florian Scotté(Université Paris-Saclay), Marie Alt(Institut Curie), Chloé Broudin(Université Paris Cité), Madeleine Ménard(Assistance Publique – Hôpitaux de Paris), Cassandre Gasne(Sorbonne Université)
Cited by 71
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Dose Escalation Methods in Phase I Cancer Clinical Trials
|JNCI Journal of the National Cancer Institute|2009|856
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
|Cancer Cell|2021|624
Progressive immune dysfunction with advancing disease stage in renal cell carcinoma
|Cancer Cell|2021|515